PharmaBoardroom

Interview: Peter Van Der Velden, Managing General Partner, Lumira…

The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and…

Interview: Riaz Bandali, President ESD, InVentiv Health Clinical,…

Riaz Bandali, President ESD of InVentiv Health Clinical discusses the ways in which the company’s unique combination of different technologies and…

Interview: Tony Cruz, Chairman and CEO, Transition Therapeutics,…

Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has…

Interview: Ying-Yih Wu, Minister of the Overseas Chinese Affairs…

The minister in charge of medical tourism in Taiwan speaks about the country's advantages over its Asian neighbours, and how the new era of Taiwan's…

VAT rates on medicine in Europe, by country, in 2013

This table shows the VAT rates applied to medicines in European countries as of 1 January 2013. (1) France: reimbursable medicines 2.1%;…

Interview: Lee-Cheng Liu, President & CEO, EirGenix, Taiwan

Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the…

Interview: Tom Reeves, CEO, Interface Biologics, Canada

Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation…

Interview: Sue Paish, CEO, LifeLabs, Canada

Sue Paish, Lifelabs’ Chief Executive Officer discusses the company’s recent purchase of BC Biomedical, why the market in BC and Ontario are so…

Interview: Michael Cloutier, President, InterMune, Canada

Michael Cloutier, President of InterMune, elaborates on the challenges of navigating the Canadian healthcare system as a small pharmaceutical company,…